Glumetinib (Synonyms: SCC244) |
| Katalog-Nr.GC64947 |
Glumetinib (SCC244) ist ein hochselektiver, oral bioverfÜgbarer, ATP-kompetitiver c-Met-Inhibitor mit einem IC50 von 0,42 nM. Glumetinib weist eine mehr als 2400-fache SelektivitÄt fÜr c-Met gegenÜber den 312 untersuchten Kinasen auf, einschließlich des c-Met-Familienmitglieds RON und der hochgradig homologen Kinasen Axl, Mer, TyrO3. Antitumor-AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1642581-63-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity[1].
Glumetinib (SCC244) (0-10 nM; 72 hours) elicits selective and profound effects against c-Met-driven cancer cell proliferation[1].Glumetinib (0-50 nM; 24 hours) induces G1-S phase cell-cycle arrest in c-Met-addicted human cancer cells[1].
Glumetinib (2.5-10 mg/kg; p.o.; once daily for 2-3 weeks) significantly inhibits c-Met-driven tumor growth in cancer CDX models[1].Glumetinib shows significant antitumor efficiency in NSCLC and HCC tumor PDX models with MET aberration[1].
[1]. Ai J, et al. Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. Mol Cancer Ther. 2018 Apr;17(4):751-762.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *